



Date: March 31, 2021

Subject: PD-L1 Testing of Patients With Lung Cancer for Immunooncology Therapies
Guideline—Reference List

RefID

1. Aguilar EJ, Ricciuti B, Gainor JF et al. Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression. *Ann Oncol*. 2019;30(10):1653-1659.
2. Ahn BC, Pyo KH, Xin CF et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. *Jf Cancer Res Clin Oncol*. 2019;145:1613-1623.
3. Antonia SJ, Balmanoukian A, Brahmer J et al. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. *J Thoracic Oncol*. 2019;14(10):1794-1806.
4. Barlesi F, Vansteenkiste J, Spigel D et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. *Lancet Oncol*. 2018;19(11):1468-1479.
5. Boothman AM, Scott M, Ratcliffe M et al. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. *J Thoracic Oncol*. 2019;14(8):1390-1399.
6. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. *NEJM*. 2015;373(17):1627-1639.
7. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *NEJM*. 2015;373(2):123-135.
8. Brunnström H, Johansson A, Westbom-Fremer S et al. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: Inter-pathologist variability is higher than assay variability. *Modern Pathol*. 2017;30(10):1411-1421.
9. Capizzi E, Ricci C, Giunchi F et al. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. *Lung Cancer*. 2018;126:9-14.
10. Chan AWH, Tong JHM, Kwan JSH et al. Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. *Modern Pathol*. 2018;31(9):1381-1390.
11. Chen J, Li H, Pang RL, Huang J. Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. *OncoTargets Ther*. 2017;10:2003-2007.
12. Cho JH, Sorensen SF, Choi YL et al. Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples. *Clin Lung Cancer*. 2017;18(6):e473-e479.
13. Cooper WA, Russell PA, Cherian M et al. Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer. *Clin, Cancer Res*. 2017;23(16):4569-4577.
14. Del CM-BP, Driver B, Morales-Rosado JA et al. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. *Arch Pathol Lab Med*. 2018;142(11):1388-1393.
15. Edahiro R, Kanazu M, Kurebe H et al. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. *PLoS ONE*. 2019;14(7)e0220570.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.



16. Elfving H, Mattsson JSM, Lindskog C, Backman M, Menzel U, Micke P. Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray. *Clin Lung Cancer*. 2019;20(4):258-262.
17. Evans M, O'Sullivan B, Hughes F et al. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. *Pathol Oncol Res*. 2018;26(1):79-89.
18. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. *Lancet*. 2016;387(10030):1837-1846.
19. Gagné A, Wang E, Bastien N et al. Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines. *J Thoracic Oncol*. 2019;14(12):2062-2070.
20. Garon EB, Hellmann MD, Rizvi NA et al. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. *J Clin Oncol*. 2019;37(28):2518-2527.
21. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. *NEJM*. 2015;372(21):2018-2028.
22. Gettinger S, Horn L, Jackman D et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. *J Clin Oncol*. 2018;36(17):1675-1684.
23. Gettinger S, Rizvi NA, Chow LQ et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2016;34(25):2980-2987.
24. Gradecki SE, Grange JS, Stelow EB. Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer. *Am J Surg Pathol*. 2018;42(8):1090-1094.
25. Grosu HB, Arriola A, Stewart J et al. PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC. *Respirol*. 2019;24(12):1198-1203.
26. Hellmann MD, Paz-Ares L, Bernabe Caro R et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. *NEJM*. 2019;381:2020-2031.
27. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. *Lancet*. 2016;387(10027):1540-1550.
28. Herbst RS, Baas P, Perez-Gracia JL et al. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of keynote-010 trial. *Ann Oncol*. 2019;30(2):281-289.
29. Hernandez A, Brandler TC, Zhou F, Moreira AL, Schatz-Siemers N, Simsir A. Assessment of programmed death-ligand 1 (PD-L1) immunohistochemical expression on cytology specimens in non-small cell lung carcinoma: A comparative study with paired surgical specimens. *Am J Clin Pathol*. 2019;151(4):403-415.
30. Horn L, Gettinger SN, Gordon MS et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. *European J Cancer*. 2018;101:201-209.
31. Hui R, Garon EB, Goldman JW et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: A phase 1 trial. *Ann Oncol*. 2017;28(4):874-881.
32. Ilie M, Long-Mira E, Bence C et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: A potential issue for anti-PD-L1 therapeutic strategies. *Ann Oncol*. 2016;27(1):147-153.
33. Keller MD, Neppl C, Irmak Y et al. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. *Mod Pathol*. 2018;31(1):101-110.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.



34. Khozin S, Carson KR, Zhi J et al. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. *Oncologist*. 2019;24(5):648-656.
35. Khozin S, Miksad RA, Adami J et al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. *Cancer*. 2019;125(22):4019-4032.
36. Kim HR, Cha YJ, Hong MH et al. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization. *Oncotarget*. 2017;8(50):87234-87243.
37. Kim HS, Cha H, Kim J et al. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. *Eur J Cancer*. 2019;120:65-74.
39. Kim S, Koh J, Kwon D et al. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. *Eur J Cancer*. 2017;75:141-149.
40. Kitazono S, Fujiwara Y, Tsuta K et al. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. *Clin Lung Cancer*. 2015;16(5):385-390.
41. Krawczyk P, Jarosz B, Kucharczyk T et al. Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes. *Oncotarget*. 2017;8(38):64283-64293.
42. Kuempers C, van der Linde LIS, Reischl M et al. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. *Virchows Archiv*. 2020;476(2):261-271.
43. Lambros L, Quintin-Roué I, Bourhis A et al. PD-L1 Immunohistochemistry-Discrepant Results between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients with Advanced Non-Small Cell Lung Cancers. *Appl Immunohistochem Mol Morphol*. 2019.
44. Li C, Huang C, Mok TS et al. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2017;12(10):1536-1543.
45. Lin SY, Yang CY, Liao BC et al. Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan. *J Cancer*. 2018;9(10):1813-1820.
46. Liu L, Bai X, Wang J et al. Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer. *Clin Cancer Res*. 2019;25(24):7413-7423.
47. Lozano MD, Abengozar-Muela M, Echeveste JI et al. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens. *Cancer Cytopathol*. 2019;127(7):470-480.
48. Mei P, Shilo K, Wei L, Shen R, Tonkovich D, Li Z. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. *Cancer Cytopathol*. 2019;127(7):447-457.
49. Mok TSK, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2019;393(10183):1819-1830.
50. Munari E, Rossi G, Zamboni G et al. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists. *Am J Surg Pathol*. 2018;42(10):1384-1389.
51. Munari E, Zamboni G, Lunardi G et al. PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. *J Thorac Oncol*. 2018;13(8):1113-1120.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.



52. Munari E, Zamboni G, Sighele G et al. Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. *Cancer Cytopathol.* 2019;127(1):52-61.
53. Naito T, Udagawa H, Sato J et al. A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. *J Thorac Oncol.* 2019;14(10):1818-1827.
54. Noll B, Wang WL, Gong Y et al. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. *Cancer Cytopathol.* 2018;126(5):342-352.
55. Oya Y, Yoshida T, Kuroda H et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. *Oncotarget.* 2017;8(61):103117-103128.
56. Pang C, Yin L, Zhou X et al. Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer. *J Thorac Dis.* 2018;10(2):816-824.
57. Peters S, Gettinger S, Johnson ML et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). *J Clin Oncol.* 2017;35(24):2781-2789.
58. Ready N, Hellmann MD, Awad MM et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. *J Clin Oncol.* 2019;37(12):992-1000.
59. Rehman JA, Han G, Carvajal-Hausdorf DE et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. *Mod Pathol.* 2017;30(3):340-349.
60. Rittmeyer A, Barlesi F, Waterkamp D et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet.* 2017;389(10066):255-265.
61. Rizvi H, Sanchez-Vega F, La K et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. *J Clin Oncol.* 2018;36(7):633-641.
62. Saito T, Tsuta K, Ishida M et al. Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients. *Lung Cancer.* 2018;125:230-237.
63. Sakata KK, Midthun DE, Mullon JJ et al. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens. *Chest.* 2018;154(4):827-837.
64. Sheffield BS, Fulton R, Kaloger SE et al. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. *J Histochem Cytochem.* 2016;64(10):587-600.
65. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer. *Ther Clin Risk Manag.* 2019;15:605-612.
66. Song P, Guo L, Li W, Zhang F, Ying J, Gao S. Clinicopathologic Correlation with Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients with Non-Small Cell Lung Cancer. *J Immunother Cancer.* 2019;42(1):23-28.
67. Tamiya M, Tamiya A, Hosoya K et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). *Invest New Drugs.* 2019;37(6):1266-1273.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.



68. Téglási V, Pipek O, Lózsa R et al. PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis. *Clin Lung Cancer*. 2019;20(5):363-369.
69. Uruga H, Bozkurtlar E, Huynh TG et al. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. *Jf Thorac Oncol*. 2017;12(3):458-466.
70. Vigliar E, Malapelle U, Iaccarino A et al. PD-L1 expression on routine samples of non-small cell lung cancer: Results and critical issues from a 1-year experience of a centralised laboratory. *J Clin Pathol*. 2019;72(6):412-417.
71. Villaruz LC, Ancevski Hunter K, Kurland BF, Abberbock S, Herbst C, Dacic S. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice. *Histopathol*. 2019;74(2):269-275.
72. Wang G, Ionescu DN, Lee CH et al. PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. *Lung Cancer*. 2019;136:1-5.
73. West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019;20(7):924-937.
74. Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, Kim KH. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. *Hum Pathol*. 2017;68:103-111.
75. Adam J, Le Stang N, Rouquette I et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. *Ann Oncol*. 2018;29(4):953-958.
76. Beck KS, Kim SJ, Kang JH, Han DH, Jung JI, Lee KY. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays. *Thorac Cancer*. 2019;10(7):1612-1618.
77. Cao R, Ma J-T, Zhang S-L et al. Rational application of the first-line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta-analysis. *Cancer Med*. 2019;8(11):5033-5046.
78. Chang H, Sasson A, Srinivasan S et al. Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. *Mol Diag Ther*. 2019;23(4):507-520.
79. Fujimoto D, Sato Y, Uehara K et al. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. *J Thorac Oncol*. 2018;13(3):377-386.
80. Fujimoto D, Yamashita D, Fukuoka J et al. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. *Anticancer res*. 2018;38(12):6891-6895.
81. Gniadek TJ, Li QK, Tully E, Chatterjee S, Nimmagadda S, Gabrielson E. Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. *Mod Pathol*. 2017;30(4):530-538.
82. Hirsch FR, McElhinny A, Stanforth D et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. *J Thorac Oncol*. 2017;12(2):208-222.
83. Humphries MP, McQuaid S, Craig SG et al. Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. *J Thorac Oncol*. 2019;14(1):45-53.
84. Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. *Cancer Cytopathol*. 2018;126(4):264-274.
85. Kim H, Kwon HJ, Park SY, Park E, Chung J-H. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. *Oncotarget*. 2017;8(58):98524-98532.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.



86. Kim R, Keam B, Hahn S et al. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. *Clin Lung Cancer*. 2019;20(5):331-338.
87. Marchetti A, Barberis M, Franco R et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. *J Thorac Oncol*. 2017;12(11):1654-1663.
88. Munari E, Zamboni G, Lunardi G et al. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. *Hum Pathol*. 2019;90:54-59.
89. Munari E, Zamboni G, Lunardi G et al. PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. *Oncotarget*. 2018;9(54):30465-30471.
90. Park HY, Oh IJ, Kho BG et al. Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression. *Tuberc Respir Dis*. 2019;82(3):227-233.
91. Parra ER, Villalobos P, Mino B, Rodriguez-Canales J. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. *Appl Immunohistochem Mol Morphol*. 2018;26(2):83-93.
92. Ratcliffe MJ, Sharpe A, Midha A et al. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. *Clin Cancer Res*. 2017;23(14):3585-3591.
93. Rimm DL, Han G, Taube JM et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. *JAMA Oncology*. 2017;3(8):1051-1058.
94. Shen K, Cui J, Wei Y et al. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. *J Thorac Dis*. 2018;10(12):6636-6652.
95. Singal G, Miller PG, Agarwala V et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. *JAMA*. 2019;321(14):1391-1399.
96. Skov BG, Skov T. Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. *Appl Immunohistochem Mol Morphol*. 2017;25(7):453-459.
97. Sughayer MA, Alnaimy F, Alsughayer AM, Qamhia N. Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC. *Appl Immunohistochem Mol Morphol*. 2019;27(9):663-666.
98. Takeda M, Kasai T, Naito M et al. Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience. *Clin Med Insights: Oncol*. 2019;13:1179554918821314.
99. Torous VF, Rangachari D, Gallant BP, Shea M, Costa DB, VanderLaan PA. PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? *J Am Soc Cytopathol*. 2018;7(3):133-141.
100. Tseng J-S, Yang T-Y, Wu C-Y et al. Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. *J Immunother*. 2018;41(6):292-299.
101. Tseng Y-H, Ho H-L, Lai C-R et al. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. *J Thorac Oncol*. 2018;13(3):447-453.
102. Wang H, Agulnik J, Kasymjanova G et al. The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma. *Lung Cancer*. 2019;132:36-38.
103. Wang H, Agulnik J, Kasymjanova G et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. *Ann Oncol*. 2018;29(6):1417-1422.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.



104. Xu H, Lin G, Huang C et al. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. *Sci Rep.* 2017;7(1):16956.
105. Xu J, Han X, Liu C et al. PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy. *Sci Rep.* 2018;8(1):11206.
106. Tsao MS, Kerr KM, Kockx M et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. *J Thorac oncol.* 2018;13(9):1302-1311.
107. Russell-Goldman E, Kravets S, Dahlberg SE, Sholl LM, Vivero M. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. *Cancer Cytopathol.* 2018;126(4):253-263.

Disclaimer

The information, data, and draft recommendations provided by the College of American Pathologists are presented for informational and public feedback purposes only.

The draft recommendations and supporting documents will be removed on May 10, 2021.

The draft recommendations along with the public comments received and completed evidence review will be reassessed by the expert panel in order to formulate the final recommendations.

These draft materials should not be stored, adapted, or redistributed in any manner.